ACADIA Pharmaceuticals Inc. Current Ratio

Current Ratio of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.


Highlights and Quick Summary

  • Current Ratio for the quarter ending March 30, 2021 was 6.16 (a -9.0% decrease compared to previous quarter)
  • Year-over-year quarterly Current Ratio decreased by -27.62%
  • Annual Current Ratio for 2020 was 6.77 (a -33.35% decrease from previous year)
  • Annual Current Ratio for 2019 was 10.16 (a 15.03% increase from previous year)
  • Annual Current Ratio for 2018 was 8.83 (a 15.95% increase from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of ACADIA Pharmaceuticals Inc.

Most recent Current Ratioof ACAD including historical data for past 10 years.

Interactive Chart of Current Ratio of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 6.16
2020 6.77 7.95 8.51 7.26 6.77
2019 10.16 10.96 6.85 6.35 10.16
2018 8.83 6.08 6.12 7.38 8.83
2017 7.62 11.12 10.85 10.82 7.62
2016 12.87 15.42 14.61 21.89 12.87
2015 10.0 13.69 14.11 18.01 10.0
2014 20.5 30.31 38.43 46.41 20.5
2013 26.99 25.24 26.59 18.08 26.99
2012 18.25 3.89 3.22 4.1 18.25
2011 5.18 5.74 6.9 7.58 5.18
2010 6.35 2.66 2.95 6.35

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.